Science Diffusion’s Post

Exciting news for Alzheimer's care: Biomarker-based diagnostic tools are revolutionizing the way we detect and treat this devastating disease. By detecting the molecular changes associated with Alzheimer's, these tests enable earlier and more accurate diagnosis, leading to more personalized and effective treatment plans. It seems incredible the signs are in the cells 20 years before symptoms appear! As we continue to make strides in the field of Alzheimer's research, the integration of diagnostic tools into routine care could reshape the way we approach and manage this complex condition. Stay tuned for more updates on how these advancements are helping to transform Alzheimer's care. #AlzheimersAwareness #MedicalAdvancements #ResearchInnovation https://lnkd.in/g3Nv8MVh

This RCT supports the importance of fibrillar amyloid reduction in multiple Alzheimer disease (AD)-related processes of neuroinflammation and neurodegeneration in cerebrospinal fluid and plasma in dominantly inherited AD. https://ja.ma/3xV812R

Are we one step closer to a blood-based screening test for Alzheimer’s? A recent study adds to a growing body of evidence that pTau217 in the blood reflects the levels of β-amyloid and tau proteins seen in brain scans and lumbar punctures. This evidence may have the potential to revolutionise diagnosis for people with suspected Alzheimer’s, a degenerative brain condition that is predicted to affect 153 million people globally by 2050. If you're developing diagnostic tests for Alzheimer's, we can provide CSF, serum and plasma samples from diagnosed Alzheimer’s patients. Samples can be accompanied with cognitive assessment scores for each donor, β-amyloid, and Total Tau values. Longitudinal samples also available. Contact us with your specifications: info@logicalbiological.com #AlzheimersAwareness #EarlyDiagnosis #patientsamples #ptau217 https://lnkd.in/eTFkvHNE

Join us for an Alzheimer's disease virtual seminar by A/Prof Christopher Chen, Yong Loo Lin School of Medicine, National University of Singapore The reconceptualization of Alzheimer's disease (AD) as a clinical and biological construct has facilitated the development of biomarker-guided, pathway-based targeted therapies, which have been approved by regulatory agencies and hence have the potential to enter global clinical practice. These advances herald an unprecedented paradigm shift and require an new global framework for clinical care pathways for AD. In this talk I shall describe how we may transition from the current, clinical symptom-focused and inherently late-stage diagnosis and management of AD to the next-generation pathway that incorporates biomarker-guided decision-making algorithms for risk stratification, early detection, timely diagnosis, and preventative or therapeutic interventions. I shall address critical high-priority challenges and propose strategic solutions such as blood biomarkers for cognitive impairment and dementia.

We are pleased to share with you our latest publication "Mitochondrial alterations in fibroblasts from sporadic Alzheimer's disease (AD) patients correlate with AD-related clinical hallmarks" in Acta Neuropathologica Communications. Please follow the link to read it ! https://lnkd.in/dHYehX_y #alzheimersdisease #alzheimerresearch #alzheimer #clinicalcorrelations #mitochondrialdyfunction

Pioneering early diagnosis of Alzheimer's disease through identification of amyloid-B oligomers in patients' cerebrospinal fluid, demonstrating potential for clinical application. #AlzheimersDisease #Chemistry #Diagnosis #FlurosecentProbes #CerebrospinalFluid #NatureCommunications https://lnkd.in/g_Qj9Hs3

In this new article, Jay Lombard, Dr. Kiran Dintyala AKA Dr. Calm, and Niranjan Kumar, PDF, Ph.D. MTM(Management, UPENN) discuss the link between periodontal disease and systemic disorders, focusing most on the association between proteases and neurological dysfunction. Therapeutic measures can target these pathological pathways, they write: https://lnkd.in/e9RywDmN #drugtargeting #drugdiscovery #periodontitis #neurologicaldisease

As a non-scientist, I have always understood #Parkinson's to be a disease that was identified by the accumulation and misfolding of the protein alpha-synuclein. I wasn't aware until recently that 80% of people with Parkinson's actually have three pathologies. In addition to the #alpha-synuclein, they have #tau (which is often associated with Alzheimers) and #beta-amyloid (β-amyloid). These layers of complexity around neurological diseases make personalized medicine even more important so that we can target the specific needs of individuals for better outcomes. Jeffrey Kordower wrote a great blog for the WPC and talked about this VERY topic on the #WPCResearchSpotlight recently with Roger Barker, WPC President. Check out his blog and interview to get up to speed on this exciting information. https://lnkd.in/epC2EcVe

New approaches to clinical endpoints for Rett syndrome are focusing on “fit-for-purpose” measures that accurately reflect the unique symptoms of this disorder. Researchers advocate for integrating advanced biomarkers and caregiver insights to enhance outcome assessment and treatment effectiveness. This shift aims to create more meaningful endpoints, ensuring that #clinicaltrials better capture the real-world impact of interventions for individuals with Rett syndrome. Learn more about this important advancement: https://bit.ly/3YfCoM6

On World Alzheimer’s Day, we at Lifescience Dynamics commemorate and champion the efforts of those who continuously fight to better the lives of patients suffering with this disease. It is an honour to support them in this work.  While Alzheimer’s disease wasn’t clinically described until 1907 by Alois Alzheimer, age-related cognitive deficiencies have long been referenced by ancient philosophers, including Pythagoras in the 6th century.  Affecting over 55 million people globally, Alzheimer’s remains the most common form of dementia (an umbrella term describing deficits in problem-solving, language, memory, and other cognitive functions). Contrary to common belief, Alzheimer's is not caused by age and instead is characterised by the slow build-up (over 20 years) of the beta-amyloid protein, tau tangles and chronic inflammation leading to neurodegeneration. Despite Alzheimer’s being clinically defined for over 100 years, Eisai’s Leqembi was the first disease-modifying therapy approved in 2023 due to the disease's complexity and limitations in early diagnostics. A year later, the FDA approved the second drug for Alzheimer’s in 2024: Eli Lilly’s amyloid targeting Kisunla. Today, the Alzheimer’s pipeline is rapidly expanding, with over 100 unique therapies in development. This offers the hope that one day Alzheimer’s will be a manageable disease. Should you like to read more on this subject, please see our recent articles below: • Remaining barriers to Alzheimer’s therapeutics following Kisunla’s approval - https://rb.gy/yhow2n  • What’s next for Alzheimer’s Disease? - https://rb.gy/zcnpxc  #WorldAlzheimersDay #AlzheimersAware #LifescienceDynamics Ivo Carre